Advanced search
Publication Cover
Scandinavian Journal of Gastroenterology Volume 54, 2019 - Issue 6
Submit an article Journal homepage
1,748
Views
9
CrossRef citations to date
0
Altmetric
Original Article

Limited relevance and progression of histological alterations in the liver during thioguanine therapy in inflammatory bowel disease patients

Dirk P. van AsseldonkDepartment of Gastroenterology and Hepatology, Noordwest Ziekenhuis groep, Alkmaar, the Netherlands;
,
Melek SimsekDepartment of Gastroenterology and Hepatology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0001-8827-955X
ORCID Icon,
Nanne K. H. de BoerDepartment of Gastroenterology and Hepatology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands;
,
Bindia JharapMeander Medical Center, Department of Gastroenterology and Hepatology, Amersfoort, the Netherlands;
,
Elisabeth BloemenaDepartment of Pathology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands;
,
Gijsbert den HartogDepartment of Gastroenterology and Hepatology, Rijnstate Hospital, Arnhem, the Netherlands;
,
Dik B. WesterveldIsala Clinics, Department of Gastroenterology and Hepatology, Zwolle, the Netherlands;
,
Marco C. BecxDepartment of Gastroenterology and Hepatology, Sint Antonius Hospital, Nieuwegein, the Netherlands;
,
Maurice G. RusselDepartment of Gastroenterology and Hepatology, Medisch Spectrum Twente, Enschede, the Netherlands;
,
Birgit I. Lissenberg-WitteDepartment of Epidemiology and Biostatistics, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands; ORCID Iconhttp://orcid.org/0000-0001-9448-1826
ORCID Icon,
Carin M. van NieuwkerkDepartment of Gastroenterology and Hepatology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands;
,
Chris J. J. MulderDepartment of Gastroenterology and Hepatology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands;
,
Joanne VerheijDepartment of Pathology, Amsterdam UMC, Academical Medical Center, Amsterdam, the Netherlands;
&
Adriaan A. van BodegravenDepartment of Gastroenterology and Hepatology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands; ;Zuyderland Medical Centre, Department of Gastroenterology, Geriatrics, Internal and Intensive Care Medicine (Co-MIK), Sittard-Geleen-Heerlen, the Netherlands
 show all
Pages 753-760 | Received 12 Mar 2019, Accepted 27 May 2019, Published online: 16 Jun 2019

References

  • Mowat C, Cole A, Windsor A. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011;60:571–607.
  • Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362:1383–1395.
  • Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146:392–400.e3.
  • Jharap B, Seinen ML, de Boer NK, et al. Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts. Inflamm Bowel Dis. 2010;16:1541–1549.
  • de Boer NK, Reinisch W, Teml A, et al. 6-Thioguanine treatment in inflammatory bowel disease: a critical appraisal by a European 6-TG working party. Digestion. 2006;73:25–31.
  • NKH d. B, Thiopurine Working Group, Ahuja V, et al. Thiopurine therapy in inflammatory bowel diseases: making new friends should not mean losing old ones. Gastroenterology. 2018;156:11–14.
  • Simsek M, Deben DS, Horjus CS, et al. Sustained effectiveness, safety and therapeutic drug monitoring of tioguanine in a cohort of 274 IBD patients intolerant for conventional therapies. Aliment Pharmacol Ther. 2019.
  • Dubinsky MC, Vasiliauskas EA, Singh H, et al. 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology. 2003;125:298–303.
  • Oancea I, Png CW, Das I, et al. A novel mouse model of veno-occlusive disease provides strategies to prevent thioguanine-induced hepatic toxicity. Gut. 2013;62:594–605.
  • van Asseldonk DP, Jharap B, Verheij J, et al. The prevalence of nodular regenerative hyperplasia in inflammatory bowel disease patients treated with thioguanine is not associated with clinically significant liver disease. Inflamm Bowel Dis. 2016;22:2112–2120.
  • Wanless IR. Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules. Hepatology. 1990;11:787–797.
  • Meijer B, Simsek M, Blokzijl H, et al. Nodular regenerative hyperplasia rarely leads to liver transplantation: a 20-year cohort study in all Dutch liver transplant units. United Eur Gastroenterol J. 2017;5:658–667.
  • Simsek M, Meijer B, Ramsoekh D, et al. Clinical course of nodular regenerative hyperplasia in thiopurine treated inflammatory bowel disease patients. Clin Gastroenterol Hepatol. 2018;17:568–570.
  • Rawat D, Gillett PM, Devadason D, et al. Long-term follow-up of children with 6-thioguanine-related chronic hepatoxicity following treatment for acute lymphoblastic leukaemia. J Pediatr Gastroenterol Nutr. 2011;53:478–479.
  • Jharap B, van Asseldonk DP, de Boer NK, et al. Diagnosing nodular regenerative hyperplasia of the liver is thwarted by low interobserver agreement. PloS One. 2015;10:e0120299.
  • Caldwell S, Lackner C. Perspectives on NASH Histology: cellular ballooning. Ann Hepatol. 2017;16:182–184.
  • Brunt EM, Janney CG, Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterology. 1999;94:2467–2474.
  • Hartleb M, Gutkowski K, Milkiewicz P. Nodular regenerative hyperplasia: evolving concepts on underdiagnosed cause of portal hypertension. World J Gastroenterol. 2011;17:1400–1409.
  • De Boer NK, Tuynman H, Bloemena E, et al. Histopathology of liver biopsies from a thiopurine-naive inflammatory bowel disease cohort: prevalence of nodular regenerative hyperplasia. Scand J Gastroenterol. 2008;43:604–608.
  • Daniel F, Cadranel JF, Seksik P, et al. Azathioprine induced nodular regenerative hyperplasia in IBD patients. Gastroenterol Clin Biol. 2005;29:600–603.
  • Vernier-Massouille G, Cosnes J, Lemann M, et al. Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine. Gut. 2007;56:1404–1409.
  • Aggarwal S, Fiel MI, Schiano TD. Obliterative portal venopathy: a clinical and histopathological review. Dig Dis Sci. 2013;58:2767–2776.
  • Ferlitsch A, Teml A, Reinisch W, et al. 6-thioguanine associated nodular regenerative hyperplasia in patients with inflammatory bowel disease may induce portal hypertension. Am J Gastroenterology. 2007;102:2495–2503.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.